Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $50.6667.

ORKA has been the subject of a number of research analyst reports. BTIG Research boosted their price target on Oruka Therapeutics from $63.00 to $73.00 and gave the company a “buy” rating in a report on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. HC Wainwright reduced their price target on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Wedbush boosted their price objective on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Finally, Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a report on Thursday, November 13th. They issued a “buy” rating and a $45.00 target price on the stock.

Insider Activity

In related news, insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $31.81, for a total transaction of $222,670.00. Following the completion of the transaction, the insider owned 1,518 shares in the company, valued at $48,287.58. The trade was a 82.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 24.69% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

Institutional investors have recently modified their holdings of the company. Legal & General Group Plc bought a new stake in Oruka Therapeutics in the 2nd quarter valued at about $28,000. Ameritas Investment Partners Inc. bought a new stake in shares of Oruka Therapeutics during the second quarter valued at approximately $31,000. BNP Paribas Financial Markets boosted its position in shares of Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after buying an additional 2,306 shares during the period. PNC Financial Services Group Inc. bought a new position in Oruka Therapeutics in the 3rd quarter worth approximately $39,000. Finally, Russell Investments Group Ltd. acquired a new stake in Oruka Therapeutics in the 3rd quarter valued at approximately $43,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

Shares of ORKA stock opened at $34.23 on Friday. The firm has a fifty day moving average of $30.93 and a two-hundred day moving average of $23.51. The firm has a market cap of $1.66 billion, a P/E ratio of -18.02 and a beta of -0.39. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $36.51.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. On average, sell-side analysts expect that Oruka Therapeutics will post -3.41 EPS for the current year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.